LabCorp Invests $2 Million in SynapDx Corporation

  LabCorp Invests $2 Million in SynapDx Corporation

        Funding to Support Upcoming Autism Diagnostic Clinical Trials

Business Wire

LEXINGTON, Mass. -- February 21, 2013

SynapDx Corporation today announced it has secured $2 million in funding from
Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE: LH). This
investment will support the clinical development of SynapDx’s breakthrough
blood-based autism spectrum disorder (ASD) diagnostic test, designed to help
clinicians identify children with autism earlier than they do today. This test
will be the first step toward SynapDx’s building of a broader pediatric
neurodevelopment testing offering.

“LabCorp and SynapDx have a shared vision about the future of diagnostics,”
said Stanley Lapidus, CEO, SynapDx. “The investment is validation of LabCorp’s
commitment to innovation and SynapDx’s transformational approach to autism
diagnostics.”

“SynapDx has the potential to revolutionize ASD diagnosis and offer
pediatricians, patients and families the opportunity to begin treatment
earlier, a key factor in improving ASD outcomes,” said David King, Chairman
and CEO, LabCorp. “We are very excited to support SynapDx’s upcoming research
efforts.”

LabCorp’s investment follows SynapDx’s recent announcement of a $6 million
round in financing supporting further development of its early ASD diagnostic
test. SynapDx is working closely with ASD experts at leading institutions
across the country and will use the investment to fund further studies slated
to begin later this year.

“LabCorp is a leader in diagnostic technology, and its strategic investment in
SynapDx demonstrates support for the development of new and better approaches
to ASD diagnosis,” said Bill Geary, Partner, North Bridge Venture Partners.

About SynapDx Corp.

SynapDx is a private company providing laboratory diagnostic services to
physicians who suspect children of developmental disorders, with the initial
goal of enabling earlier detection of autism spectrum disorders (ASDs). The
company collaborates with ASD experts at leading institutions, including
Boston Children’s Hospital. SynapDx was founded in 2010 and is based in
Lexington, Mass. Its investors include North Bridge Venture Partners and
General Catalyst Partners.

Contact:

Lois Paul and Partners
Susan McCarron, 617-986-5767
Susan_mccarron@lpp.com